Neutrophil–lymphocyte ratio is a predictor of prognosis in patients with castration-resistant prostate cancer: a meta-analysis

References

• SiegelRMaJZouZJemalACancer statistics, 2014.CA Cancer J Clin201464192924399786
   PubMed Web of Science ®Google Scholar
• HeidenreichABastianPJBellmuntJEAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancerEur Urol201465246747924321502
   PubMed Web of Science ®Google Scholar
• FriedlanderTWRyanCJTargeting the androgen receptorUrol Clin North Am201239445346423084523
   PubMed Web of Science ®Google Scholar
• BertholdDRPondGRSobanFde WitREisenbergerMTannockIFDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 studyJ Clin Oncol200826224224518182665
   PubMed Web of Science ®Google Scholar
• TannockIFde WitRBerryWRDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar
• de BonoJSOudardSOzgurogluMPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialLancet201037697471147115420888992
   PubMed Web of Science ®Google Scholar
• FroehnerMWirthMPEnzalutamide in metastatic prostate cancer before chemotherapyN Engl J Med20143711817551755
   PubMed Web of Science ®Google Scholar
• ScherHIFizaziKSaadFIncreased survival with enzalu-tamide in prostate cancer after chemotherapyN Engl J Med2012367131187119722894553
   PubMed Web of Science ®Google Scholar
• BerrutiAPiaATerzoloMAbiraterone and increased survival in metastatic prostate cancerN Engl J Med20113658766766
   PubMedGoogle Scholar
• RyanCJSmithMRde BonoJSAbiraterone in metastatic prostate cancer without previous chemotherapyN Engl J Med2013368213814823228172
   PubMed Web of Science ®Google Scholar
• ParkerCNilssonSHeinrichDAlpha emitter radium-223 and survival in metastatic prostate cancerN Engl J Med2013369321322323863050
   PubMed Web of Science ®Google Scholar
• PezaroCAttardGProstate cancer in 2011: redefining the therapeutic landscape for CRPCNat Rev Urol201292636422249187
   PubMed Web of Science ®Google Scholar
• KowalewskaMNowakRChechlinskaMImplications of cancer-associated systemic inflammation for biomarker studiesBiochim Biophys Acta20101806216317120600631
   PubMed Web of Science ®Google Scholar
• SaitoKKiharaKC-reactive protein as a biomarker for urological cancersNat Rev Urol201181265966622025173
   PubMed Web of Science ®Google Scholar
• Akinci OzyurekBSahin OzdemirelTBuyukyaylaci OzdenSErdoganYKaplanBKaplanTPrognostic value of the neutrophil to lymphocyte ratio (NLR) in lung cancer casesAsian Pac J Cancer Prev20171851417142128612596
   PubMedGoogle Scholar
• OrdituraMGaliziaGDianaANeutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysisESMO Open201612e00003827843594
   PubMedGoogle Scholar
• HaHNamARBangJHSoluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapyOncotarget2016747766047661227780932
   PubMedGoogle Scholar
• LiSXuXLiangDTianGSongSHeYPrognostic value of blood neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with gastric cancerZhonghua Zhong Liu Za Zhi2014361291091525623765
   PubMedGoogle Scholar
• LorenteDMateoJTempletonAJBaseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid useAnn Oncol201526475075525538172
   PubMed Web of Science ®Google Scholar
• CorreaRGKrajewskaMWareCFGerlicMReedJCThe NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signalingOncotarget2014561666168224681825
   PubMedGoogle Scholar
• NuhnPVaghasiaAMGoyalJAssociation of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxelBJU Int20141146bE11E1724529213
   PubMed Web of Science ®Google Scholar
• BoegemannMSchlackKThomesSThe role of the neutrophil to lymphocyte ratio for survival outcomes in patients with metastatic castration-resistant prostate cancer treated with abirateroneInt J Mol Sci2017182380
   PubMed Web of Science ®Google Scholar
• MehraNSharpALorenteDNeutrophil to lymphocyte ratio in castration-resistant prostate cancer patients treated with daily oral corticosteroidsClin Genitourin Cancer201715667868428606735
   PubMed Web of Science ®Google Scholar
• UemuraKKawaharaTYamashitaDNeutrophil-to-lymphocyte ratio predicts prognosis in castration-resistant prostate cancer patients who received cabazitaxel chemotherapyBiomed Res Int201720177538647753865528948170
   PubMed Web of Science ®Google Scholar
• TierneyJFStewartLAGhersiDBurdettSSydesMRPractical methods for incorporating summary time-to-event data into meta-analysisTrials200781617555582
   PubMed Web of Science ®Google Scholar
• HandollHHSystematic reviews on rehabilitation interventionsArch Phys Med Rehabil200687687516731227
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
   PubMed Web of Science ®Google Scholar
• LorenteDMateoJTempletonAJBaseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid useAnn Oncol201526475075525538172
   PubMed Web of Science ®Google Scholar
• LintonAPondGClarkeSVardyJGalskyMSonpavdeGGlasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapyClin Geni-tourin Cancer2013114423430
   PubMed Web of Science ®Google Scholar
• YaoASejimaTIwamotoHHigh neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapyInt J Urol201522982783326087772
   PubMed Web of Science ®Google Scholar
• McLachlanJMChanDLCrumbakerMAMarxGMNeutrophil– lymphocyte ratio prior to steroids as a prognostic marker in men with metastatic castration-resistant prostate cancerCancer Treat Commun201548185
   Google Scholar
• van SoestRJTempletonAJvera-BadilloFENeutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trialsAnn Oncol201526474374925515657
   PubMed Web of Science ®Google Scholar
• SümbülATSezerAAbalıHNeutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxelInt Urol Nephrol20144681531153524526335
   PubMed Web of Science ®Google Scholar
• ConteducaVCrabbSJJonesRJPersistent neutrophil to lymphocyte ratio >3 during treatment with enzalutamide and clinical outcome in patients with castration-resistant prostate cancerPLoS One2016117e015895227434372
   PubMed Web of Science ®Google Scholar
• PeiXQHeDLTianGPrognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern ChinaInt Urol Nephrol201749462963528161841
   PubMed Web of Science ®Google Scholar
• ButtiglieroCPisanoCTucciMPrognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxelActa Oncol201756455556228068151
   PubMed Web of Science ®Google Scholar
• SonpavdeGPondGRArmstrongAJPrognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancerClin Genitourin Cancer201412531732424806399
   PubMed Web of Science ®Google Scholar
• TempletonAJPezaroCOmlinASimple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratioCancer2014120213346335224995769
   PubMed Web of Science ®Google Scholar
• LolliCCaffoOScarpiESystemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abirateroneFront Pharmacol2016737627790145
   PubMed Web of Science ®Google Scholar
• IshiokaJSaitoKSakuraMDevelopment of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysisBr J Cancer201210771031103622918396
   PubMed Web of Science ®Google Scholar
• CoffeltSBKerstenKDoornebalCWIL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasisNature2015522755634534825822788
   PubMed Web of Science ®Google Scholar
• TazzymanSNiazHMurdochCNeutrophil-mediated tumour angiogenesis: subversion of immune responses to promote tumour growthSemin Cancer Biol201323314915823410638
   PubMed Web of Science ®Google Scholar
• GrivennikovSIGretenFRKarinMImmunityKMImmunity, inflammation, and cancerCell2010140688389920303878
   PubMed Web of Science ®Google Scholar
• RamanathanSGagnonJIlangumaranSAntigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancerArch Immunol Ther Exp2008565311323
   PubMed Web of Science ®Google Scholar
• MuranskiPRestifoNPAdoptive immunotherapy of cancer using CD4(+) T cellsCurr Opin Immunol200921220020819285848
   PubMed Web of Science ®Google Scholar
• CaoJZhuXZhaoXLiXFXuRNeutrophil-to-lymphocyte ratio predicts PSA response and prognosis in prostate cancer: a systematic review and meta-analysisPLoS One2016117e015877027368058
   PubMed Web of Science ®Google Scholar
• GuXGaoXLiXPrognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patientsSci Rep201662208926912340
   PubMed Web of Science ®Google Scholar
• TangLLiXWangBPrognostic value of neutrophil-to-lymphocyte ratio in localized and advanced prostate cancer: a systematic review and meta-analysisPLoS One2016114e015398127096158
   PubMed Web of Science ®Google Scholar
• AlkhouriNMorris-StiffGCampbellCNeutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver diseaseLiver Int201232229730222097893
   PubMed Web of Science ®Google Scholar
• BaltaSCakarMDemirkolSArslanZAkhanMHigher neutrophil to lymphocyte ratio in patients with metabolic syndromeClin Appl Thromb Hemost201319557923344995
   PubMed Web of Science ®Google Scholar
• SuttonAJSongFGilbodySMAbramsKRModelling publication bias in meta-analysis: a reviewStat Methods Med Res20009542144511191259
   PubMed Web of Science ®Google Scholar